Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Chène

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Molecular Cancer Research : MCR|February 6, 2004
Inhibition of the p53-MDM2 interaction: targeting a protein-protein interfacePatrick Chène
Cell Cycle (Georgetown, Tex.)|February 21, 2004
Inhibition of the p53-hdm2 interaction with low molecular weight compoundsPatrick Chène
Drug Discovery Today|February 14, 2012
Can biochemistry drive drug discovery beyond simple potency measurements?Patrick Chène
Drug Discovery Today|June 14, 2008
Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinasesPatrick Chène
Chemmedchem|August 8, 2006
Drugs targeting protein-protein interactionsPatrick Chène
Nature Reviews. Drug Discovery|September 5, 2002
ATPases as drug targets: learning from their structurePatrick Chène
Nature Reviews. Cancer|February 4, 2003
Inhibiting the p53-MDM2 interaction: an important target for cancer therapyPatrick Chène
Expert Opinion on Therapeutic Targets|June 5, 2003
The ATPases: a new family for a family-based drug design approachPatrick Chène
Chemmedchem|June 12, 2024
Direct Inhibition of the YAP : TEAD Interaction: An Unprecedented Drug Discovery ChallengePatrick Chène
Cancer Letters|July 27, 2002
The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramersAnnemieke Atema, Patrick Chène
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Molecular Cancer Research : MCR|February 6, 2004
Inhibition of the p53-MDM2 interaction: targeting a protein-protein interfacePatrick Chène
Cell Cycle (Georgetown, Tex.)|February 21, 2004
Inhibition of the p53-hdm2 interaction with low molecular weight compoundsPatrick Chène
Drug Discovery Today|February 14, 2012
Can biochemistry drive drug discovery beyond simple potency measurements?Patrick Chène
Drug Discovery Today|June 14, 2008
Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinasesPatrick Chène
Chemmedchem|August 8, 2006
Drugs targeting protein-protein interactionsPatrick Chène
Nature Reviews. Drug Discovery|September 5, 2002
ATPases as drug targets: learning from their structurePatrick Chène
Nature Reviews. Cancer|February 4, 2003
Inhibiting the p53-MDM2 interaction: an important target for cancer therapyPatrick Chène
Expert Opinion on Therapeutic Targets|June 5, 2003
The ATPases: a new family for a family-based drug design approachPatrick Chène
Chemmedchem|June 12, 2024
Direct Inhibition of the YAP : TEAD Interaction: An Unprecedented Drug Discovery ChallengePatrick Chène
Cancer Letters|July 27, 2002
The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramersAnnemieke Atema, Patrick Chène
Pageof 6